STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 7, 2026, 04:04 PM

SIGA Technologies Q1 Net Loss $(3.5)M; Expects $35M+ TPOXX Deliveries

AI Summary

SIGA Technologies reported a net loss of $(3.5) million, or $(0.05) diluted loss per share, for Q1 2026, compared to a net loss of $(0.4) million in Q1 2025. Total revenues decreased to $6.2 million from $7.0 million year-over-year. Despite the Q1 losses, the company expects to deliver over $35 million of TPOXX to the U.S. Government and an international customer across Q2 and Q3 2026, including $13 million of oral TPOXX in Q2 and $26 million of IV TPOXX by Q3. Additionally, SIGA declared a special cash dividend of $0.60 per share and entered into an exclusive license agreement for oral TPOXX in the MENA region.

Key Highlights

  • Q1 2026 net loss was $(3.5) million, compared to $(0.4) million in Q1 2025.
  • Diluted loss per share for Q1 2026 was $(0.05), compared to $(0.01) in Q1 2025.
  • Total revenues for Q1 2026 were $6.2 million, down from $7.0 million in Q1 2025.
  • Expects to deliver $13 million of oral TPOXX to an international customer in Q2 2026.
  • Expects to deliver $26 million of IV TPOXX to the U.S. Government by end of Q3 2026.
  • Declared a special cash dividend of $0.60 per share, paid on April 23, 2026.
  • Signed an exclusive license agreement for oral TPOXX in the MENA region in March 2026.
SIGA
Biotechnology: Pharmaceutical Preparations
SIGA TECHNOLOGIES INC

Price Impact